Stockscreener 앱 받기
44.42
0.57%
0.25
시장 영업 전:
44.82
0.40
+0.90%
전일 마감가:
$44.17
열려 있는:
$44.45
하루 거래량:
3.56M
Relative Volume:
1.29
시가총액:
$11.28B
수익:
$2.32B
순이익/손실:
$782.57M
주가수익비율:
15.96
EPS:
2.7838
순현금흐름:
$875.84M
1주 성능:
-1.14%
1개월 성능:
+1.23%
6개월 성능:
+10.03%
1년 성능:
+11.50%
1일 변동 폭
$44.13
$45.21
1주일 범위
$43.50
$45.41
52주 변동 폭
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.42 | 11.28B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
Exelixis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exelixis Q1 2026 slides: revenue grows 10%, zanzalintinib advances - Investing.com
Exelixis Q1 Earnings Call Highlights - Yahoo Finance
Transcript : Exelixis, Inc., Q1 2026 Earnings Call, May 05, 2026 - marketscreener.com
Exelixis (EXEL) Q1 2026 Earnings Transcript - AOL.com
Earnings call transcript: Exelixis beats Q1 2026 forecasts, stock rises - Investing.com
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Exelixis Posts Strong Q1 Results, Expands Share Buybacks - TipRanks
Exelixis (EXEL) Tops Q1 Earnings Estimates - Yahoo Finance
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum - ChartMill
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.58B - marketscreener.com
Exelixis Q1 Non-GAAP Earnings, Revenue Rise - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76 - marketscreener.com
Exelixis: Q1 Earnings Snapshot - kare11.com
Exelixis (NASDAQ: EXEL) boosts Q1 2026 earnings, cash and buybacks - Stock Titan
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, Vs. FactSet Est of $0.76 - Moomoo
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can RCC franchise weather competition? - Investing.com
MSN Money - MSN
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - Caledonian Record
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative - Yahoo Finance
Behavioral Patterns of EXEL and Institutional Flows - Stock Traders Daily
Earnings Preview: Exelixis to Report Financial Results Post-market on May 05 - Moomoo
Vanguard Capital Management (NASDAQ: EXEL) reports 5.09% stake - Stock Titan
Exelixis (EXEL) is a top-ranked value stock: Should you buy? - MSN
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC - ChartMill
Will Exelixis (EXEL) beat estimates again in its next earnings report? - MSN
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Why Exelixis (EXEL) is a top value stock for the long term - MSN
Do Options Traders Know Something About Exelixis Stock We Don't? - msn.com
Exelixis, Inc. (EXEL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings Spark Investor Interest - DirectorsTalk Interviews
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Exelixis Inc (BSP:E2XE34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Exelixis (BSP:E2XE34) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BSP:E2XE34 ROE %: 45.26% — 110% Above Median - GuruFocus
Exelixis Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Exelixis Inc (BSP:E2XE34) Stock Today? - GuruFocus
Exelixis (BSP:E2XE34) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
Exelixis Inc (BSP:E2XE34) Dividend - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price, Trades & News - GuruFocus
Exelixis Inc (BSP:E2XE34)Valuation Measures & Financial Statistics - GuruFocus
Exelixis Inc Stock Baskets | BSP:E2XE34 - GuruFocus
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):